Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Avlayah Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentCareSourcePolicy N/A

    Avlayah (tividenofusp alfa-eknm) for Mucopolysaccharidosis Type II

    Customize your policy alerts

    Sign up for all CareSource policy alerts

    Know when CareSource releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical prior authorization coverage for Avlayah for neurologic manifestations of MPS II in pediatric CareSource Arkansas PASSE members, including initial authorization and reauthorization requirements.

    Policy Summary
    PayerCareSource
    PolicyAvlayah (tividenofusp alfa-eknm) for MPS II
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateOct 1, 2026
    Last ReviewApr 13, 2026
    Next Review DateN/A
    Key ActionSubmit baseline cerebrospinal fluid heparan sulfate and hemoglobin documentation with the medical prior authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    A new policy was created establishing coverage criteria for Avlayah (tividenofusp alfa-eknm) for MPS II.

    ≥5 kgMinimum member weight
    <18 yearsMaximum age
    6 monthsInitial authorization
    15 mg/kg weeklyMaximum dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 months
    Reauthorization

    Coverage Criteria

    Initial Therapy Criteria

    Covered for initial authorization when all of the following are met:

    Initial authorization

    • Eligibility: Member is male, weighs at least 5 kg, and is less than 18 years of age.male; ≥5 kg; <18 years
    • Prescriber qualification: Avlayah is prescribed by or in consultation with a geneticist, metabolic specialist, neurologist, or pediatrician experienced with managing mucopolysaccharidoses.
    • ONE accepted diagnostic pathway

      • Enzyme testing: Testing shows low iduronate 2-sulfatase (IDS) enzyme activity and normal activity of a second sulfatase enzyme to exclude Multiple Sulfatase Deficiency.low IDS activity; normal second sulfatase activity
      • Molecular testing: Molecular genetic testing identifies a pathogenic IDS gene mutation.pathogenic IDS gene mutation
    • Baseline documentation: Baseline cerebrospinal fluid (CSF) heparan sulfate level and baseline hemoglobin level are documented.
    • Neurologic status: Member does not have advanced neurologic impairment, based on the clinical judgment of the specialist.no advanced neurologic impairment
    • Concomitant therapy: Avlayah is not being used in combination with other enzyme replacement therapies.no combination enzyme replacement therapy

    Continuation Therapy Criteria

    Covered for reauthorization when all of the following are met:

    Continuation therapy

    • Clinical response: Chart notes show improvement or stabilized signs and symptoms of disease, including neurologic and/or somatic signs and symptoms.improvement or stabilization
    • Biomarker response: Documentation shows a reduced cerebrospinal fluid (CSF) heparan sulfate level from baseline.reduced CSF heparan sulfate from baseline

    Avlayah must not be used in combination with other enzyme replacement therapies.

    Avlayah is not medically necessary for treatment of conditions or indications not listed in this policy. Other indications should be referred to the Off-Label policy.

    Dose and Eligibility Parameters

    Minimum Member Weight
    Minimum weightAt least 5 kg
    Eligible populationPresymptomatic or symptomatic pediatric male patients
    Neurologic statusTreatment must be initiated before advanced neurologic impairment
    Member Age
    Age requirementLess than 18 years of age
    PopulationPediatric members
    Authorization stageApplies to initial authorization

    Authorization and Documentation Requirements

    Prior Authorization

    Medical Prior Authorization Required

    Medical prior authorization is required for Avlayah (tividenofusp alfa-eknm). When initial authorization criteria are met, approval is issued for 6 months; reauthorization, when criteria continue to be met, is issued for an additional 6 months.

    • Dose may be titrated up to 15 mg/kg once weekly by intravenous infusion, per prescribing information.
    Documentation Required

    Baseline Laboratory Documentation

    Document baseline laboratory values before treatment to support authorization and future reassessment.

    • Baseline cerebrospinal fluid (CSF) heparan sulfate level is required.
    • Baseline hemoglobin level is required.

    Clinical Background

    Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is an X-linked lysosomal storage disease caused by deficient or absent iduronate 2-sulfatase. Accumulation of heparan sulfate and dermatan sulfate causes progressive multisystem damage, including neurologic manifestations. Avlayah is a brain-penetrant enzyme replacement therapy designed to cross the blood-brain barrier and is used for neurologic manifestations when initiated before advanced neurologic impairment; its indication received accelerated approval based on reduction of cerebrospinal fluid heparan sulfate.

    Key Definitions

    Mucopolysaccharidosis Type II (MPS II)
    DefinitionA rare X-linked lysosomal storage disease
    Alternate nameHunter syndrome
    Cause and characteristicCaused by deficient or absent iduronate 2-sulfatase and characterized by accumulation of glycosaminoglycans
    Heparan Sulfate
    SubstrateA glycosaminoglycan substrate
    Disease roleAccumulates in MPS II
    Biomarker roleMeasured in cerebrospinal fluid as a treatment-response biomarker

    Initial Authorization

    Initial Authorization

    Initial authorization is available when all of the following requirements are met:

    Initial Avlayah authorization

    • Member eligibility: Member is male, weighs at least 5 kg, and is less than 18 years of age.male; ≥5 kg; <18 years
    • Qualified prescriber: Medication is prescribed by or in consultation with a geneticist, metabolic specialist, neurologist, or pediatrician experienced with managing mucopolysaccharidoses.
    • ONE accepted diagnostic pathway

      • Enzyme confirmation:

    Reauthorization

    Reauthorization

    Reauthorization is available when all of the following requirements are met:

    • Clinical response: Chart notes show improvement or stabilized signs and symptoms of disease, including neurologic and/or somatic signs and symptoms.improvement or stabilization
    • Biomarker response: Documentation shows a reduced cerebrospinal fluid (CSF) heparan sulfate level from baseline.reduced CSF heparan sulfate from baseline

    Quantity and Administration Limits

    Avlayah Quantity Limits
    MedicationAvlayah (tividenofusp alfa-eknm)
    Titrated doseUp to 15 mg/kg
    FrequencyOnce weekly
    Infusion routeIV infusion
    Policy Summary
    PayerCareSource
    PolicyAvlayah (tividenofusp alfa-eknm) for MPS II
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateOct 1, 2026
    Last ReviewApr 13, 2026
    Next Review DateN/A
    Key ActionSubmit baseline cerebrospinal fluid heparan sulfate and hemoglobin documentation with the medical prior authorization request.
    SourceLink
    On This Page
    Coverage CriteriaDose and Eligibility ParametersAuthorization and Documentation RequirementsClinical BackgroundKey DefinitionsInitial AuthorizationReauthorizationQuantity and Administration Limits
    Avlayah Dosage and Quantity Limit
    Maximum doseTitrate up to 15 mg/kg
    FrequencyOnce weekly
    RouteIntravenous infusion
    Documentation Required

    MPS II Diagnostic Confirmation

    Document diagnostic confirmation of MPS II (Hunter syndrome) using at least one accepted testing pathway.

    • Low iduronate 2-sulfatase (IDS) enzyme activity with normal activity of a second sulfatase enzyme to exclude Multiple Sulfatase Deficiency; and/or
    • Molecular genetic testing identifying a pathogenic IDS gene mutation.
    Documentation Required

    Reauthorization Documentation

    For reauthorization, submit chart notes demonstrating ongoing benefit and objective disease response.

    • Chart notes must show improvement or stabilization of neurologic and/or somatic signs and symptoms.
    • Document a reduced CSF heparan sulfate level from baseline.
    Denial Risk

    Initial Authorization Criteria Not Met

    Initial authorization should be denied when any required eligibility, prescribing, clinical, or treatment condition is not met.

    • Member is not male, weighs less than 5 kg, or is 18 years of age or older.
    • Medication is not prescribed by or in consultation with a geneticist, metabolic specialist, neurologist, or pediatrician experienced in managing mucopolysaccharidoses.
    • Member has advanced neurologic impairment according to the clinical judgment of the specialist.
    • Required MPS II diagnostic confirmation or baseline laboratory documentation is absent.
    • Avlayah is being used with another enzyme replacement therapy.
    Denial Risk

    Combination Enzyme Replacement Therapy

    Concurrent use of Avlayah with another enzyme replacement therapy is not permitted under the initial authorization criteria and creates a denial risk.

    • Avlayah must not be used in combination with other enzyme replacement therapies, including therapy intended for MPS II.
    Denial Risk

    Reauthorization Response Criteria Not Met

    Reauthorization should be denied when the required evidence of continued response is not documented.

    • Deny if chart notes do not show improvement or stabilization of neurologic and/or somatic disease signs and symptoms.
    • Deny if a reduced CSF heparan sulfate level from baseline is not documented.
    BBB
    Full termBlood-brain barrier
    Avlayah relevanceAvlayah is designed to cross the blood-brain barrier
    Therapeutic purposeEnables delivery of iduronate 2-sulfatase to the brain to address central nervous system symptoms
    Low iduronate 2-sulfatase (IDS) enzyme activity is present with normal activity of a second sulfatase enzyme to exclude Multiple Sulfatase Deficiency.
    low IDS activity; normal second sulfatase activity
  1. Molecular confirmation: Molecular genetic testing identifies a pathogenic IDS gene mutation.pathogenic IDS gene mutation
  2. Baseline laboratory documentation: Baseline cerebrospinal fluid (CSF) heparan sulfate level and baseline hemoglobin level are documented.
  3. Neurologic status: Member does not have advanced neurologic impairment, based on the clinical judgment of the specialist.no advanced neurologic impairment
  4. Treatment combination: Avlayah is not being used in combination with other enzyme replacement therapies.no combination enzyme replacement therapy